Illumina (NASDAQ:ILMN) Price Target Cut to $330.00 by Analysts at Canaccord Genuity

Illumina (NASDAQ:ILMN) had its price target decreased by Canaccord Genuity from $377.00 to $330.00 in a research report report published on Friday, The Fly reports. Canaccord Genuity currently has a buy rating on the life sciences company’s stock.

Several other brokerages also recently commented on ILMN. Zacks Investment Research downgraded GasLog Partners LP Unit from a hold rating to a strong sell rating in a research note on Tuesday, April 2nd. Wolfe Research initiated coverage on Waters in a research note on Thursday, May 30th. They issued an underperform rating for the company. BidaskClub upgraded Zumiez from a sell rating to a hold rating in a research note on Saturday, June 22nd. Bank of America set a $80.00 price target on Colgate-Palmolive and gave the company a buy rating in a research note on Friday. Finally, OTR Global downgraded Illumina to a positive rating in a research note on Tuesday, April 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have assigned a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $341.15.

Shares of ILMN opened at $302.29 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.33 and a current ratio of 3.66. The company has a 50-day moving average price of $343.54. The firm has a market cap of $44.84 billion, a P/E ratio of 52.85, a PEG ratio of 2.12 and a beta of 1.15. Illumina has a one year low of $268.62 and a one year high of $380.76.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 25th. The life sciences company reported $1.60 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.34 by $0.26. The company had revenue of $846.00 million during the quarter, compared to the consensus estimate of $838.70 million. Illumina had a return on equity of 23.49% and a net margin of 25.06%. The firm’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same period last year, the business posted $1.45 EPS. Equities research analysts predict that Illumina will post 6.68 earnings per share for the current fiscal year.

In other Illumina news, SVP Charles Dadswell sold 124 shares of Illumina stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $311.77, for a total transaction of $38,659.48. Following the transaction, the senior vice president now owns 8,086 shares of the company’s stock, valued at approximately $2,520,972.22. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jay T. Flatley sold 3,300 shares of Illumina stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $376.50, for a total transaction of $1,242,450.00. Following the transaction, the director now directly owns 272,616 shares in the company, valued at approximately $102,639,924. The disclosure for this sale can be found here. In the last three months, insiders have sold 59,291 shares of company stock worth $19,459,234. Insiders own 0.38% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. CENTRAL TRUST Co grew its stake in Illumina by 249.1% in the 2nd quarter. CENTRAL TRUST Co now owns 995 shares of the life sciences company’s stock valued at $362,000 after buying an additional 710 shares in the last quarter. Sheets Smith Wealth Management purchased a new position in shares of Illumina during the 2nd quarter valued at $382,000. Diversified Trust Co grew its position in shares of Illumina by 11.0% during the 2nd quarter. Diversified Trust Co now owns 5,513 shares of the life sciences company’s stock valued at $2,030,000 after purchasing an additional 545 shares in the last quarter. Handelsbanken Fonder AB grew its position in shares of Illumina by 45.6% during the 2nd quarter. Handelsbanken Fonder AB now owns 60,653 shares of the life sciences company’s stock valued at $22,329,000 after purchasing an additional 19,000 shares in the last quarter. Finally, Xact Kapitalforvaltning AB grew its position in shares of Illumina by 6.6% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 31,221 shares of the life sciences company’s stock valued at $11,494,000 after purchasing an additional 1,931 shares in the last quarter. 89.81% of the stock is currently owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Article: How does the Federal Reserve determine interest rates?

The Fly

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.